Skip to main content
. 2012 Mar 22;12:107. doi: 10.1186/1471-2407-12-107

Table 1.

Characteristics of 137 patients treated with sunitinib due to advanced GIST

Clinicopathological features No of patients (%)
Total number of patients 137 (100)

Age [years] at the start of therapy with sunitinib Median (range) 55 (15-82)

≤45 14 (10)

> 45 123 (88)

Gender Female 63 (46)

Male 74 (54)

Primary tumor site Stomach 46 (33.5)

small bowel 79 (57.6)

large bowel/rectum 4 (2.9)

other or intraperitoneally with unknown primary origin 8 (5.8)

Time on imatinib therapy ≤ 6 months (early resistance) 25 (18.2)

6-12 months 16 (11.7)

> 12 months 96 (70.1)

Primary reason for stop of imatinib therapy Disease progression 135 (98.5)

Imatinib intolerance 2 (1.5)

ECOG Performance Status 0 48 (35)

1 72 (52.6)

≥2 17 (12.4)

Tumor genotype* Exon 11 KIT mutation 52 (58.4)

Exon 9 KIT mutation 15 (16.9)

PDGFRA mutation 12 (13.5)

Wild-type 10 (11.2)

Data not available 48

* mutational status was evaluated in 89 cases (65%)